[The pharmacological properties of Midodrin and its clinical application in patients with hypotensive circulatory disturbance (author's transl)].
D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004983:Ethanolamines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D005998:Glycine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006261:Headache / Q000139:chemically induced; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006873:Hydroquinones / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D007022:Hypotension / Q000188:drug therapy*; D007024:Hypotension, Orthostatic / Q000188:drug therapy; D008297:Male; D012893:Sleep Wake Disorders / Q000139:chemically induced; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014717:Vertigo / Q000139:chemically induced
D004983:Ethanolamines; D006873:Hydroquinones; D014662:Vasoconstrictor Agents; D005998:Glycine
Pharmakologie von Midodrin sowie dessen klinische Austestung bei hypotoner Regulationsstörung des Kreislaufes